There’s no single “best” medication to lower A1C — the right drug depends on your heart and kidney health, weight goals, hypoglycemia risk, and cost, not just your A1C number. The American Diabetes Association’s 2025 Standards of Care recommends starting from these individual factors first, then choosing among metformin, GLP-1 receptor agonists, SGLT2 inhibitors, or insulin based on what will help you most, not from a single default drug for everyone.
That can be a frustrating answer if you’re hoping for a straightforward ranking. But understanding why doctors don’t pick one universal “best” drug — and what they weigh instead — will help you have a much more productive conversation at your next appointment.
There’s No Universal Answer — Here’s What Doctors Weigh Instead
For years, treatment guidelines defaulted almost everyone to metformin first, then added other drugs only as A1C climbed. The American Diabetes Association’s 2025 Standards of Care shifted that approach: for many people, the choice of medication is now driven by existing health conditions and risk factors independent of A1C, not just by how high the number is.
In practice, that means two people with the identical A1C of 8.0% could walk out of the clinic with different prescriptions, because one has heart disease and the other has kidney disease and neither has the same weight goals.
Metformin: Still Often the Starting Point
Metformin remains a common first medication for many newly diagnosed patients — it’s inexpensive, well studied, and generally safe, though the ADA no longer treats it as an automatic, universal first step for every single patient. Read more in our guide to metformin and other medication options.
Where things get more individualized is what happens next, or what’s added alongside metformin (or sometimes instead of it) based on your specific health profile.
Tolerability is also part of the picture. According to Mayo Clinic, the most common metformin side effects are digestive — nausea, gas, diarrhea, or an upset stomach — and these tend to be strongest when starting the medication or increasing the dose, often easing over time. Long-term use can also lower vitamin B12 levels in some people, which is one reason your care team periodically checks bloodwork. If side effects are significant for you, that’s worth raising directly — it may change which medication makes sense.
The Factors That Actually Steer the Decision
According to current ADA guidance, your doctor is weighing several things at once, not just your latest A1C:
- Heart disease risk. If you have established cardiovascular disease or a high risk of it, an SGLT2 inhibitor and/or a GLP-1 receptor agonist with proven heart benefits is recommended — regardless of your A1C level and whether or not you’re also on metformin.
- Heart failure. For adults with heart failure (with reduced or preserved ejection fraction), an SGLT2 inhibitor is specifically recommended, both for blood sugar control and to help prevent heart failure hospitalizations.
- Kidney disease (CKD). SGLT2 inhibitors also help slow the progression of chronic kidney disease, though their glucose-lowering effect weakens once kidney function (eGFR) drops below a certain threshold — your care team will check your kidney labs before and during treatment.
- Weight and obesity. If weight loss is a treatment goal, GLP-1 receptor agonists and dual GIP/GLP-1 medications are often prioritized because of their significant effect on body weight, in addition to lowering blood sugar.
- Hypoglycemia risk. Older adults, people with a history of severe low blood sugar, or anyone with an unpredictable schedule may be steered toward drug classes with a lower risk of hypoglycemia.
- Cost and insurance coverage. Newer drug classes like GLP-1s can be expensive or inconsistently covered, which is a legitimate and common factor in the decision — ask your care team about patient assistance programs if cost is a barrier.
- Your own preference. Pill versus injection, dosing frequency, and side-effect tolerance are all valid parts of the conversation.
How the Major Drug Classes Compare
A quick orientation to the classes your doctor is choosing among (see our full Type 2 Diabetes Medications guide for a deeper breakdown of each):
- Metformin — low cost, decades of safety data, modest A1C reduction, generally weight-neutral.
- GLP-1 receptor agonists (e.g., semaglutide, dulaglutide) — strong A1C reduction plus meaningful weight loss and cardiovascular benefit; usually injectable, though oral options exist.
- SGLT2 inhibitors — protect the heart and kidneys independent of blood sugar control; work by having the kidneys remove excess glucose through urine.
- Dual GIP/GLP-1 agonists like tirzepatide — combine two hormone pathways for some of the largest A1C and weight reductions currently available; see our comparison of tirzepatide versus other GLP-1 drugs.
- Insulin — the most powerful glucose-lowering option and sometimes necessary regardless of other factors, especially with very high A1C at diagnosis; our insulin therapy guide explains when and how it’s typically introduced.
Several newer combination therapies and drug classes have also reached the market in recent years — see our roundup of new type 2 diabetes treatments for what’s changed most recently.
What This Looks Like in a Real Conversation With Your Doctor
A useful way to prepare for your appointment is to walk in ready to discuss, not just your A1C, but your full picture: any history of heart or kidney problems, your weight goals, how you feel about injections versus pills, your budget and insurance formulary, and how often you’ve had low blood sugar in the past. The more of that picture your doctor has, the more precisely they can match a medication (or combination) to you specifically, rather than defaulting to whatever is “typical.”
It’s also worth asking directly: “Given my heart, kidney, and weight situation, which medications are you weighing for me, and why?” That question tends to surface the individualized reasoning the ADA guidelines are built around.
If Your First Medication Doesn’t Get You to Target
Not reaching your individual A1C goal on the first medication isn’t a failure — it’s common, and it’s exactly what the follow-up visits are for. Rather than abandoning a drug at the first sign it isn’t enough on its own, care teams typically add a second (or third) medication from a different class, aiming to combine complementary benefits — for example, pairing metformin with an SGLT2 inhibitor for added heart and kidney protection, or adding a GLP-1 receptor agonist when weight loss and stronger A1C reduction are both goals.
Your individual A1C target itself is also personalized: the ADA notes that goals can be adjusted looser or tighter depending on your age, how long you’ve had diabetes, other health conditions, and your risk of hypoglycemia, rather than everyone being held to the same fixed number.
How Fast Do These Medications Lower A1C?
Effects vary by drug class, dose, and the individual, and your doctor will typically recheck your A1C roughly every three months when starting or adjusting therapy, per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Because red blood cells live about three months, A1C reflects an average — it won’t fully show a medication’s effect until roughly one testing cycle has passed, even though blood sugar itself may improve much sooner.
Frequently Asked Questions
Is metformin still the medication almost everyone starts on?
It’s still commonly used as an initial medication, but current guidelines no longer treat it as an automatic universal first step — some people with heart, kidney, or weight-related risk factors may start on or add an SGLT2 inhibitor or GLP-1 receptor agonist earlier, independent of their A1C.
Can diet and exercise replace medication entirely?
For some people, especially early after diagnosis, lifestyle changes alone can meaningfully lower A1C, and in some cases delay or reduce the need for medication. But this varies by individual and should be a decision made with your care team, not decided alone — untreated high blood sugar carries real risks.
How often will my medication be adjusted?
Most care teams reassess roughly every three months using your A1C result, alongside how you’re tolerating the medication and any changes in your heart, kidney, or weight status, adjusting the plan as needed.
What if I can’t afford a GLP-1 or SGLT2 medication?
Cost is a real and common barrier, not a minor detail — tell your care team directly rather than skipping doses or stopping quietly. Many manufacturers offer patient assistance or savings programs, your insurance formulary may cover an alternative in the same class, and in some cases a different drug class can achieve a similar goal at lower cost. Pharmacists are also a good resource for identifying lower-cost options.
Last updated July 2, 2026.
This article is for education and is not medical advice; talk to your clinician about which medication is right for you.
